Hepatitis C virus:A global view

被引：8

作者：

Amal Ahmed Mohamed ^{[1
]}

Tamer A Elbedewy ^{[2
]}

Magdy El-Serafy ^{[3
]}

Naglaa El-Toukhy ^{[4
]}

Wesam Ahmed ^{[5
]}

Zaniab Ali El Din ^{[5
]}

机构：

[1] Biochemistry Department,National Hepatology and Tropical Medicine Institute

[2] Internal Medicine Department, Faculty of Medicine, Tanta University

[3] Tropical Department, National Hepatology and Tropical Medicine Institute

[4] Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Benha University

[5] Internal Medicine Depart- ment, Faculty of Medicine, Ain Shams University

来源：

World Journal of Hepatology | 2015年 / 26期

关键词：

Hepatitis C; Peginterferon; Sofosbuvir; Direct-acting antivirals;

D O I：

暂无

中图分类号：

R373.21 [];

学科分类号：

100103 ; 100705 ;

摘要：

Hepatitis C virus(HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma(HCC), and end-stage liver disease. Management of chronic HCV is aimed at preventing cirrhosis, reducing the risk of HCC, and treating extra hepatic complications. New treatments for chronic HCV has been devoted based on direct-acting antivirals, as pegylated interferon(peginterferon) is responsible for many side effects and limits treatment access. Sofosbuvir is the first compound to enter the market with Peginterferon-free combination regimens.

引用

页码：2676 / 2680

页数：5

共 15 条

[1]

Wael Abdel‐Razek,Imam Waked.Optimal therapy in genotype 4 chronic hepatitis C: finally cured?[J].Liver Int,2015

[2] Global Distribution and Prevalence of Hepatitis C Virus Genotypes [J].

Messina, Jane P. ;

Humphreys, Isla ;

Flaxman, Abraham ;

Brown, Anthony ;

Cooke, Graham S. ;

Pybus, Oliver G. ;

Barnes, Eleanor .

HEPATOLOGY, 2015, 61 (01) :77-87

[3]

Donald B. Smith,Jens Bukh,Carla Kuiken,A. Scott Muerhoff,Charles M. Rice,Jack T. Stapleton,Peter Simmonds.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource[J].Hepatology,2014(1)

[4]

Roberta D’Ambrosio,Massimo Colombo.Safety of direct antiviral agents in real life[J].Digestive and Liver Disease,2013

[5]

Alessio Aghemo,Elisabetta Degasperi,Massimo Colombo.Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials[J].Digestive and Liver Disease,2013

[6]

Martel-LaferriÃ¨re, ValÃ©rie,Dieterich, Douglas T.GS-7977: a promising nucleotide analog NS5B polymerase inhibitor of HCV[J].Future Virology,2012

[7] Evolving epidemiology of hepatitis C virus [J].

Lavanchy, D. .

CLINICAL MICROBIOLOGY AND INFECTION, 2011, 17 (02) :107-115

[8] Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver [J].

Jacobson, Ira M. ;

Cacoub, Patrice ;

Dal Maso, Luigino ;

Harrison, Stephen A. ;

Younossi, Zobair M. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (12) :1017-1029

[9]

Thomas Berg,Michael von Wagner,Samer Nasser,Christoph Sarrazin,Tobias Heintges,Tilman Gerlach,Peter Buggisch,Tobias Goeser,Jens Rasenack,Gerd R. Pape,Wolfgang E. Schmidt,Birgit Kallinowski,Hartwig Klinker,Ulrich Spengler,Peter Martus,Ulrich Alshuth,Stefan Zeuzem.Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin[J].Gastroenterology,2006(4)

[10] Current therapy for hepatitis C [J].

Friedrich-Rust, Mireen ;

Zeuzem, Stefan ;

Sarrazin, Christoph .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2007, 22 (04) :341-349

← 1 2 →